What MCAS patients actually report — in their own words.
A signal dashboard built from public discussion on Reddit, surfacing the treatments patients try, how many fall outside approved labels, where care falls short, and the side effects they live with.
Why this matters: Mast Cell Activation Syndrome is a young diagnosis. Approved therapies are scarce, evidence of efficacy is thin, and clinical protocols remain weak — so patients self-experiment and share what works. These signals are self-reported and unverified, but they map a real-world treatment landscape the literature hasn’t caught up with.
75
distinct substances mentioned
71%
of posts with a treatment class mention an off-label one
2.5
avg. substances per patient mentioning any
91%
report needs still unmet
01 · Symptom profile
Top symptoms reported
Share of posts mentioning symptoms (n = 754) that report a symptom from this class. Patients often report several symptoms per post, so shares overlap. Click a card to see its subcategories.
Shortness of breath · Throat tightness · Nasal congestion
Other respiratory or airway symptom10%
Shortness of breath8%
Throat tightness8%
Nasal congestion7%
Cough2%
Wheezing1%
Air hunger1%
Cardiovascular and orthostatic25%▸
Lightheadedness · Tachycardia · Palpitations
Lightheadedness10%
Tachycardia8%
Other cardiovascular or orthostatic symptom6%
Palpitations6%
Fainting3%
Low blood pressure3%
Orthostatic intolerance1%
Orthostatic dizziness0%
Musculoskeletal15%▸
Muscle aches
Other musculoskeletal symptom8%
Muscle aches6%
Joint pain4%
Muscle spasms2%
Bone pain1%
Muscle twitching1%
Headache and head symptoms14%▸
Headache · Migraine
Headache9%
Migraine5%
Head pressure1%
Other head symptom1%
02 · Treatment landscape
What patients say they take
Ranked by share of authors mentioning each treatment class, substance and brand (n = 751). The tag comes from the treatment class.
Antihistamine (H1)On-label
30.5%
Mast cell stabilizerOff-label
23.6%
Antihistamine (H2)On-label
19.0%
OtherOff-label
15.0%
BiologicOff-label
6.1%
Leukotriene receptor antagonistOff-label
5.2%
Emergency epinephrineOn-label
3.3%
CorticosteroidOff-label
3.2%
FamotidineOn-label
17.0%
CromolynOff-label
16.4%
KetotifenOff-label
12.4%
CetirizineOn-label
11.6%
FexofenadineOn-label
10.3%
OmalizumabOff-label
6.0%
LoratadineOn-label
5.2%
MontelukastOff-label
5.2%
PepcidOn-label
9.5%
ZyrtecOn-label
8.3%
AllegraOn-label
6.9%
XolairOff-label
5.9%
BenadrylOn-label
5.1%
ClaritinOn-label
4.1%
EpipenOn-label
2.1%
SingulairOff-label
1.6%
Access & cost profile of mentioned treatments
Share of treatment mentions (distinct author–treatment pairs, n = 934) — over-the-counter, off-patent generic prescription, or on-patent branded drug.
OTC · 43%
Generic Rx · 38%
On-patent
Unassigned
Over-the-counter
43%
Famotidine, Cetirizine, Fexofenadine, Loratadine
Generic Rx
38%
Cromolyn, Ketotifen, Montelukast, Epinephrine
On-patent / branded
9%
Omalizumab, Tirzepatide, Rhapsido, Tezepelumab
Types of treatment, substances and respective brands
Posts mentioning each treatment class, substance and brand, supplements excluded (n = 494 posts). Click a class to zoom in, click "All classified" to zoom out; hover a box for exact numbers.